We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

87 hedge funds and large institutions have $263M invested in Relmada Therapeutics in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 36 increasing their positions, 12 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

606% more call options, than puts

Call options by funds: $5.55M | Put options by funds: $785K

200% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 12

15% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 13

2% more funds holding

Funds holding: 85 → 87 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1.79% less ownership

Funds ownership: 59.19% → 57.4% (-1.8%)

17% less capital invested

Capital invested by funds: $316M → $263M (-$53.7M)

Holders
87
Holders Change
+2
Holders Change %
+2.35%
% of All Funds
1.52%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
36
Reduced
12
Closed
13
Calls
$5.55M
Puts
$785K
Net Calls
+$4.76M
Net Calls Change
-$3M

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$11.3M
2
Millennium Management
Millennium Management
New York
+$6.38M
3
GTC
Ghost Tree Capital
New York
+$5.35M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$3.83M
5
BBA
Baker Bros. Advisors
New York
+$3.33M

Top Sellers

1
ACA
Avoro Capital Advisors
New York
-$29.9M
2
IC
Ikarian Capital
Texas
-$7.48M
3
BlackRock
BlackRock
New York
-$6.96M
4
TA
Tiedemann Advisors
New York
-$1.78M
5
Charles Schwab
Charles Schwab
California
-$1.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$40.3M – – –
VA
2
VR Adviser
New York
$36.4M – – –
BlackRock
3
BlackRock
New York
$31.7M -$6.96M -259,866 -18%
Vanguard Group
4
Vanguard Group
Pennsylvania
$24M +$3.83M +142,947 +19%
PCM
5
Parsons Capital Management
Rhode Island
$12.4M +$604K +22,562 +5%
Morgan Stanley
6
Morgan Stanley
New York
$11.8M +$11.3M +422,982 +1,605%
Citadel Advisors
7
Citadel Advisors
Florida
$9.85M +$344K +12,869 +4%
State Street
8
State Street
Massachusetts
$8.54M +$420K +15,707 +5%
Millennium Management
9
Millennium Management
New York
$6.67M +$6.38M +238,351 +1,469%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$6.65M +$251K +9,371 +4%
Franklin Resources
11
Franklin Resources
California
$6.37M – – –
Point72 Asset Management
12
Point72 Asset Management
Connecticut
$5.77M +$682K +25,490 +13%
BBA
13
Baker Bros. Advisors
New York
$5.27M +$3.33M +124,396 +162%
GTC
14
Ghost Tree Capital
New York
$5.24M +$5.35M +200,000 New
Bank of New York Mellon
15
Bank of New York Mellon
New York
$5.19M -$31.9K -1,190 -0.6%
Northern Trust
16
Northern Trust
Illinois
$4.28M +$182K +6,807 +4%
CAC
17
Cowen and Company
New York
$4.18M – – –
MP
18
Mangrove Partners
Connecticut
$4.17M +$3M +112,192 +239%
SSA
19
Schonfeld Strategic Advisors
New York
$2.96M +$1.48M +55,177 +96%
TCM
20
Tang Capital Management
California
$2.62M – – –
Alkeon Capital Management
21
Alkeon Capital Management
New York
$2.62M +$1.34M +50,000 +100%
Norges Bank
22
Norges Bank
Norway
$2.58M +$2.64M +98,500 New
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
23
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$2.34M +$2.39M +89,400 New
Goldman Sachs
24
Goldman Sachs
New York
$2.26M +$2.1M +78,637 +1,056%
N
25
Nuveen
North Carolina
$1.59M +$65K +2,427 +4%
1
2 3 4

RLMD Hedge Fund Activity: Q3 2021 in Review

87 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q3 2021, worth a combined $263M — down 17% from $316M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new RLMD positions and 13 closed out — a net gain of 2 holders — while 36 added to existing stakes and 12 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $11.3M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $29.9M sold.

  • 87 institutional investors held Relmada Therapeutics (RLMD) as of Q3 2021, up from 85 in Q2 2021.
  • Funds reported $263M of Relmada Therapeutics stock for Q3 2021, down 17% quarter-over-quarter.
  • 15 funds opened new Relmada Therapeutics positions in Q3 2021 and 13 closed out, a net change of +2 holders.
  • The largest Relmada Therapeutics buyer in Q3 2021 was Morgan Stanley, an estimated $11.3M added.
  • The largest Relmada Therapeutics seller in Q3 2021 was Avoro Capital Advisors, an estimated $29.9M sold.

Based on aggregated 13F filings for Q3 2021.